PRQR — ProQR Therapeutics NV Share News
0.000.00%
Last trade - 00:00- $182.05m
- $68.00m
- €16.35m
ProQR Therapeutics NV reports results for the quarter ended in June - Earnings Summary
Brief: ProQR Therapeutics, Laboratoires Théa Announce Agreement For Théa To Acquire ProQR's Sepofarsen, Ultevursen Ophthalmic Assets
ProQR Therapeutics NV expected to post a loss of 11 cents a share - Earnings Preview
ProQR Therapeutics NV reports results for the quarter ended in March - Earnings Summary
Brief: ProQR Announces First Quarter 2023 Operating And Financial Results
ProQR Therapeutics NV expected to post a loss of 11 cents a share - Earnings Preview
ProQR Therapeutics NV reports results for the quarter ended in December - Earnings Summary
Brief: ProQR Therapeutics Files Prospectus Relates To Resale Of Up To 13.4 Mln Shares By Selling Shareholders
Brief: ProQR Announces Initial Pipeline Targets, Highlights Axiomer RNA Editing
ProQR Therapeutics NV expected to post a loss of 17 cents a share - Earnings Preview
ProQR Therapeutics NV expected to post a loss of 17 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-ProQR Therapeutics, IsoPlexis Corp, Tesla, AMC Entertainment
U.S. STOCKS ON THE MOVE-ProQR Therapeutics, IsoPlexis Corp, Tesla
ProQR Therapeutics soars on expanding collaboration with Lilly
U.S. STOCKS ON THE MOVE-Mirati Therapeutics, CarMax, ORIC Pharmaceuticals
U.S. STOCKS ON THE MOVE-ProQR Therapeutics, TuSimple, ORIC Pharmaceuticals
ProQR Therapeutics surges on expanded collaboration with Lilly
ProQR Therapeutics NV reports results for the quarter ended in September - Earnings Summary
Brief: Proqr Announces Q3 2022 Operating And Financial Results